Acumen Pharmaceuticals, Inc.

06/18/2026

At Acumen, we know that our greatest strength is our people.

This pride month, we celebrate the LGBTQ+ community and reaffirm our commitment to creating a workplace where everyone feels welcomed, respected, and empowered to be themselves.

Diverse perspectives make us stronger, and we are proud to foster a culture where people can thrive, both personally and professionally.

06/16/2026

We’re excited to share that Acumen has nominated two Enhanced Brain Delivery™ candidates for development in the treatment of Alzheimer’s disease.

We will advance both candidates by combining our AβO-selective antibody expertise and JCR Pharmaceuticals’ validated transferrin-receptor-targeting blood-brain barrier-penetrating technology, termed J-Brain Cargo®, as part of our ongoing collaboration. This differentiated approach potentially addresses a critical challenge in delivering Alzheimer’s therapeutics across the blood-brain barrier.

Please see our press release for more information: https://investors.acumenpharm.com/news-releases/news-release-details/acumen-pharmaceuticals-announces-nomination-two-enhanced-brain

06/09/2026

At Acumen, we believe in putting people first, and what better way to do that than by shining a spotlight on our incredible team members and the amazing work they do!

June's 'Ask Acumen' featured team member is Liean Schenck, Senior Vice President, Head of CMC.

🔗Click the link to get a behind-the-scenes look at Liean's journey, passions, and outstanding contributions to our mission: https://acumenpharm.com/ask-acumen/

06/02/2026

June is Alzheimer’s & Brain Awareness Month.

More than 55 million people worldwide are living with dementia, and millions of family members, friends, and caregivers are navigating its impact every day.

At Acumen, our work is driven by the urgency of Alzheimer’s disease and the profound effect it has on individuals, families, and communities. This month serves as a reminder of the importance of advancing research, supporting brain health, and continuing the pursuit of meaningful progress for people affected by Alzheimer’s.

To learn more about Alzheimer’s disease, brain health, and available resources, visit the Alzheimer’s Association at www.alz.org/abam.

05/28/2026

We’re excited to share a new publication from our team in 'Trials' highlighting patient experiences from the Phase 1 INTERCEPT-AD study of sabirnetug (ACU193).

The manuscript, “Elucidating the phase 1 trial experience among study participants following completion of the INTERCEPT-AD study of sabirnetug (ACU193) for early Alzheimer’s disease: a qualitative interview study,” offers valuable insights into participant perspectives and experiences following trial completion, to potentially inform future clinical trial design and engagement strategies.

🔗Read the publication here: https://doi.org/10.1186/s13063-026-09656-w

Background Recruitment and retention remain persistent challenges in Alzheimer’s disease (AD) clinical trials, particularly as studies increasingly focus on earlier disease stages and require longer participation and more invasive procedures. Understanding how trial enrollment and participation ar...

05/20/2026

On , we honor and thank the entire clinical trial community; especially the patients, caregivers, and families whose participation makes progress possible.

We’re deeply grateful to everyone contributing to our ongoing Phase 2 ALTITUDE-AD trial of sabirnetug, and we remain relentless in our pursuit of next-generation treatments for Alzheimer’s disease.

05/12/2026

Today we announced our first quarter financial results and business highlights.

🔗Click the link to read the full release: https://investors.acumenpharm.com/news-releases/news-release-details/acumen-pharmaceuticals-reports-first-quarter-2026-financial

05/06/2026

At Acumen, we believe in putting people first, and what better way to do that than by shining a spotlight on our incredible team members and the amazing work they do!

May's 'Ask Acumen' featured team member is Brandon Duncan, Staff Accountant.

🔗Click the link to get a behind-the-scenes look at Brandon's journey, passions, and outstanding contributions to our mission: https://acumenpharm.com/ask-acumen/

04/24/2026

This week our CMO Eric Siemers MD presented a poster titled “Expected Centiloid Values for Patients with Positive Visual Reads of Amyloid PET Scans” at the American Academy of Neurology (AAN) conference in Chicago. The presentation includes research on expected range of Centiloid (CL) values from amyloid positron emission tomography (PET) scans assessed as positive by visual reads based on published literature and baseline clinical trial results.

04/08/2026

At Acumen, we believe in putting people first, and what better way to do that than by shining a spotlight on our incredible team members and the amazing work they do!

April's 'Ask Acumen' featured team member is Amber Dilley, Senior Director, Quality Assurance.

🔗Click the link to get a behind-the-scenes look at Amber's journey, passions, and outstanding contributions to our mission: https://acumenpharm.com/ask-acumen